A Catalio-initiated liquid biopsy diagnostic company developing a best-in-class assay for the detection of minimal residual disease (MRD) to improve cancer patient outcomes. Â
Surgery remains the standard of care for most early-stage solid tumors, but most cancers recur.  Tracking progression of disease after treatment remains challenging, and it can be months or years before recurrent disease is detected by routine diagnostic work ups. Haystackâs bespoke liquid biopsy assay detects a patientâs tumor-specific markers via blood sample to identify residual disease following treatment.  The companyâs patented technology offers best-in-class sensitivity resulting in earlier detection of recurrent disease and improved outcomes for millions of cancer patients each year.â¯
Surgery remains the standard of care for most early-stage solid tumors, but most cancers recur.  Tracking progression of disease after treatment remains challenging, and it can be months or years before recurrent disease is detected by routine diagnostic work ups. Haystackâs bespoke liquid biopsy assay detects a patientâs tumor-specific markers via blood sample to identify residual disease following treatment.  The companyâs patented technology offers best-in-class sensitivity resulting in earlier detection of recurrent disease and improved outcomes for millions of cancer patients each year.â¯
Location: United States
Employees: 11-50
Total raised: $56M
Founded date: 2021
Investors 3
| Date | Name | Website |
| 15.11.2022 | Johns Hopk... | ventures.j... |
| - | Catalio Ca... | cataliocap... |
| - | Endless Fr... | endlessfro... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.11.2022 | Series A | $56M | - |
Mentions in press and media 6
| Date | Title | Description |
| 15.09.2025 | The Scientist Unveils the 2025 Top Innovations Award Winners | The Scientist Top 10 Innovations of 2025 Fourteen breakthrough technologies are recognized across biotechnology, healthcare, lab tools, and startup innovations. WILMINGTON, Del., Sept. 15, 2025 /PRNewswire-PRWeb/ -- The Scientist proudly an... |
| 16.11.2022 | HLTH22 Day 3 News Summary | DispatchHealth Raises $330M for Hospital-at-Home Care DexCare Announces 50-state Project with Kaiser Permanente Providence spin-out, DexCare, announced an expanded partnership with Kaiser that’ll make health system care accessible in all 50... |
| 16.11.2022 | Haystack Oncology Raises $56M in Series A Funding | Haystack Oncology, a Baltimore, MD-based oncology company, raised $56M in Series A funding. The round was led by Catalio Capital Management, with participation from Bruker, Exact Ventures, and Alexandria Venture Investments. As part of this... |
| 16.11.2022 | Haystack Oncology Launches with $56M in Series A | BALTIMORE, MD, Haystack Oncology announced that it raised $56 million in Series A financing. >> Click here for more funding data on Haystack Oncology >> To export Haystack Oncology funding data to PDF and Excel, click here ... |
| 16.11.2022 | Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech | What You Should Know: Haystack was co-founded in 2021 by Drs. Bert Vogelstein, Ken Kinzler and Nick Papadopoulos, and Mr. Joshua Cohen of Johns Hopkins University, alongside CEO Dan Edelstein and CTO Dr. Frank Holtrup. Drs. Vogelstein, Kinz... |
| - | Haystack Oncology | “Make better decisions with better MRD testing Unmatched sensitivity and specificity for confident MRD detection. Arriving Soon. Get notified MRD testing See what other tests can’t Haystack Oncology uses the next generation of circulating t... |